PlasmaGen Biosciences secures ₹150 crore to expand into global markets
Biopharmaceutical company PlasmaGen Biosciences raised ₹150 crore in a new round of equity financing, valuing the company at over ₹1,500 crore. ViNS Bioproducts, a specialty biopharma company, picked up a…
Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr
Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company’s standalone net profit surged to Rs 54.68 crore in Q3 FY 25 as compared with Rs 15.80 crore in…








